Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bremelanotide + pde5 inhibitor
- Development stage
- Unknown
- Lead developer
- Palatin Technologies
- Modality
- Peptides, Small Molecules
- Administration
- Subcutaneous
01
Overview
Bremelanotide is a synthetic peptide agonist of the melanocortin 4 receptor. It acts centrally in the brain to enhance sexual desire and arousal. PDE5 inhibitors (such as sildenafil, tadalafil, or vardenafil) are small molecules that act in the penis to facilitate blood flow and erection by inhibiting the breakdown of cyclic guanosine monophosphate (cGMP). The combination of bremelanotide and a PDE5 inhibitor is being developed for men with erectile dysfunction (ED) who do not respond to PDE5 inhibitor monotherapy, representing a significant unmet need, as approximately 30–40% of ED patients are "PDE5i non-responders"[1][2][5]. The product in development is a unique, injectable co-formulation of both drugs, intended for single-dose administration.
- Other names
- Bremelanotide and PDE5 inhibitorBMT + PDE5iPT-141 and PDE5 inhibitorPT141 and PDE5 inhibitorPT 141 and PDE5 inhibitor
02
Targets
MC4R (Melanocortin 4 receptor)MC1R (Melanocortin Type 1 Receptor)MC2R (Adrenocorticotropic Hormone Receptor)MC3R (Melanocortin Receptor Type 3)PDE5 (Phosphodiesterase 5A)MC5R (Melanocortin 5 Receptor)
Beyond the preview
Go deeper on bremelanotide + pde5 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bremelanotide + pde5 inhibitor.